Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

2,589 questions in 168 reviews · Schizophrenia

current versions

No studies 601 · 23.2%Ungraded 446 · 17.2%Very low 721 · 27.8%Low 505 · 19.5%Moderate 274 · 10.6%High 42 · 1.6%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
HALOPERIDOL vs OTHER ANTIPSYCHOTICS: g. QUETIAPINE Repeated need for tranquillisation ‐ not reported · psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs OTHER ANTIPSYCHOTICS: g. QUETIAPINE Specific behaviour ‐ agitation · psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	1 study · 80 participants	Low
HALOPERIDOL vs OTHER ANTIPSYCHOTICS: g. QUETIAPINE Global outcome ‐ not reported · psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs PLACEBO/NIL Adverse effects: Specific ‐ dystonia within 24 hours · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 7.49 [0.93, 60.21]	2 studies · 207 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTICS: g. QUETIAPINE Adverse effects · psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 1.81 [1.19, 2.77]	1 study · 80 participants	Low
HALOPERIDOL vs OTHER ANTIPSYCHOTICS: g. QUETIAPINE Economic outcome ‐ not reported · psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE Tranquillisation or asleep ‐ not asleep · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 0.84 [0.74, 0.95]	1 study · 162 participants	Moderate
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE Repeated need for rapid tranquillisation ‐ needing additional benzodiazepine · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 0.98 [0.65, 1.47]	2 studies · 286 participants	Low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE Specific behaviours ‐ agitation >50% reduction in PANSS‐EC score · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 1.15 [0.6, 2.22]	1 study · 124 participants	Low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE Global outcome ‐ rated as severe ‐ CGI‐S · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 0.89 [0.51, 1.58]	1 study · 162 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE Adverse effects: Specific ‐ EPS during 24 hours · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 1.6 [0.55, 4.62]	1 study · 124 participants	Low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE Adverse effects: Specific ‐ acute dystonia during 24 hours · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 5 [0.24, 102.07]	2 studies · 286 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE Economic outcome ‐ not reported · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE Tranquillisation or asleep ‐ not reported · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs PLACEBO/NIL Economic outcome ‐ not reported · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE Repeated need for rapid tranquillisation · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 1.07 [0.89, 1.28]	1 study · 30 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE Specific behaviour ‐ threat or injury to self or others ‐ not reported · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE Global outcome No improvement at 1 hour · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 0.5 [0.14, 1.84]	1 study · 44 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE Adverse effects: specific ‐ hypotensive episode · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	1 study · 30 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE Adverse effects: specific ‐ tachycardia · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 0.28 [0.01, 6.52]	1 study · 44 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE Economic outcome ‐ not reported · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE Tranquilisation or asleep ‐ not reported · psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE Repeated need for tranquilisation · psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 1.64 [1.07, 2.53]	1 study · 60 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE Specific behaviour ‐ agitation · psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	1 study · 231 participants	Low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE Global outcome · psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	1 study · 132 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE Tranquillisation or asleep ‐ not reported · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE Adverse effects: Specific ‐ dystonia during 72 hours · psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 10.26 [1.67, 63.17]	2 studies · 508 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE Adverse effects: Specific ‐ clinically significant abnormal ECG during 72 hours · psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 1.01 [0.6, 1.71]	1 study · 376 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE Economic outcome ‐ not reported · psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: k. ZUCLOPENTHIXOL ACETATE Tranquillisation or asleep ‐ not reported · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: k. ZUCLOPENTHIXOL ACETATE Repeated need for rapid tranquillisation ‐ more than 3 injections · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 2.54 [1.19, 5.46]	1 study · 70 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: k. ZUCLOPENTHIXOL ACETATE Specific behaviour ‐ threat or injury to self or others ‐ not reported · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: k. ZUCLOPENTHIXOL ACETATE Global outcome ‐ not reported · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: k. ZUCLOPENTHIXOL ACETATE Adverse effects: specific ‐ tremor by 7 days · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 4.16 [0.93, 18.62]	1 study · 70 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: k. ZUCLOPENTHIXOL ACETATE Economic outcome ‐ not reported · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs BENZODIAZEPINE: a. FLUNITRAZEPAM Tranquillisation or asleep ‐ not reported · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE Repeated need for rapid tranquillisation ‐ needing additional injection · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 0.78 [0.62, 0.99]	2 studies · 473 participants	Low
HALOPERIDOL vs BENZODIAZEPINE: a. FLUNITRAZEPAM Repeated need for tranquillisation within 24 hours ‐ not reported · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs BENZODIAZEPINE: a. FLUNITRAZEPAM Specific behaviours ‐ aggression 50% reduction in OAS score at 90 minutes · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 1.15 [0.86, 1.55]	1 study · 28 participants	Very low
HALOPERIDOL vs BENZODIAZEPINE: a. FLUNITRAZEPAM Global outcome ‐ need for restraint or seclusion · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	1 study · 28 participants	Very low
HALOPERIDOL vs BENZODIAZEPINE: a. FLUNITRAZEPAM Adverse effects: specific ‐ EPS · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	1 study · 28 participants	Very low
HALOPERIDOL vs BENZODIAZEPINE: a. FLUNITRAZEPAM Economic outcome ‐ not reported · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs BENZODIAZEPINE: b. LORAZEPAM Tranquillisation or asleep not asleep at 60 minutes · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 1.05 [0.76, 1.44]	1 study · 60 participants	Very low
HALOPERIDOL vs BENZODIAZEPINE: b. LORAZEPAM Repeated need for rapid tranquillisation more than 1 injection · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 1.14 [0.91, 1.43]	1 study · 66 participants	Very low
HALOPERIDOL vs BENZODIAZEPINE: b. LORAZEPAM Specific behaviour ‐ threat or injury to self or others within 24 hours ‐ not reported · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs BENZODIAZEPINE: b. LORAZEPAM Global outcome: no overall improvement ‐ at 60 minutes · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 1.64 [0.54, 5.03]	1 study · 44 participants	Very low
HALOPERIDOL vs BENZODIAZEPINE: b. LORAZEPAM Adverse effects: specific ‐ dystonia (only reported if occurred in ≥9% during 24 hours) · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 3.54 [0.42, 30.03]	1 study · 66 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE Specific behaviours ‐ agitation: CABS average change score at 2 hours · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	2 studies · 470 participants	Very low
HALOPERIDOL vs BENZODIAZEPINE: b. LORAZEPAM Adverse effects: specific ‐ hypertonia/rigidity (only reported if occurred in ≥9%) during 24 hours · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 6.22 [0.33, 115.91]	1 study · 66 participants	Very low
HALOPERIDOL vs BENZODIAZEPINE: b. LORAZEPAM Economic outcome ‐ not reported · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies